HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Exenatide once weekly for the treatment of type 2 diabetes.

Abstract
Exenatide is the first glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus (T2DM). Exenatide lowers blood glucose through multiple mechanisms, including enhancement of glucose-dependent insulin secretion, suppression of excess glucagon secretion, reduction of food intake and slowing of gastric emptying. The current formulation of exenatide requires twice-daily dosing (exenatide BID), and an extended-release formulation of exenatide is now in development for use as a once-weekly injection (exenatide QW). The purpose of this report is to review the most current clinical data on the development of exenatide QW for the treatment of T2DM. In clinical trials, exenatide QW significantly improved glycemic control, resulted in patient weight loss, and was well tolerated in patients with T2DM. In a head-to-head clinical trial, exenatide QW caused greater improvements in glycemic control and was better tolerated than exenatide BID. Given the rapidly increasing prevalence of diabetes and obesity worldwide, exenatide QW is a promising development candidate for the treatment of T2DM.
AuthorsJames Malone, Michael Trautmann, Ken Wilhelm, Kristin Taylor, David M Kendall
JournalExpert opinion on investigational drugs (Expert Opin Investig Drugs) Vol. 18 Issue 3 Pg. 359-67 (Mar 2009) ISSN: 1744-7658 [Electronic] England
PMID19243286 (Publication Type: Journal Article, Review)
Chemical References
  • Glycated Hemoglobin A
  • Peptides
  • Venoms
  • hemoglobin A1c protein, human
  • Exenatide
Topics
  • Animals
  • Clinical Trials as Topic
  • Diabetes Mellitus, Type 2 (blood, drug therapy)
  • Drug Tolerance
  • Exenatide
  • Glycated Hemoglobin (metabolism)
  • Humans
  • Peptides (administration & dosage, chemistry, pharmacology, therapeutic use)
  • Treatment Outcome
  • Venoms (administration & dosage, chemistry, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: